Our data suggested that FOXO4 plays a key role in the regulation of glycolysis in GC, and disrupting the HIF‐1α‐FOXO4‐LDHA axis might be a promising therapeutic strategy for GC. This evidence concerns the gene HIF1A and gastric cancer.